PE20061038A1 - Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion - Google Patents
Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacionInfo
- Publication number
- PE20061038A1 PE20061038A1 PE2006000202A PE2006000202A PE20061038A1 PE 20061038 A1 PE20061038 A1 PE 20061038A1 PE 2006000202 A PE2006000202 A PE 2006000202A PE 2006000202 A PE2006000202 A PE 2006000202A PE 20061038 A1 PE20061038 A1 PE 20061038A1
- Authority
- PE
- Peru
- Prior art keywords
- chlorophenyl
- oxadiazole
- alkyl
- alcoxy
- halogen
- Prior art date
Links
- 229940124802 CB1 antagonist Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- 150000002367 halogens Chemical class 0.000 abstract 4
- -1 2-CHLOROPHENYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- GEAXLHPORCRESC-UHFFFAOYSA-N chlorocyclohexatriene Chemical class ClC1=CC=C=C[CH]1 GEAXLHPORCRESC-UHFFFAOYSA-N 0.000 abstract 2
- CYAYCOCJAVHQSD-UHFFFAOYSA-N 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid Chemical compound CC=1C(C(O)=O)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 CYAYCOCJAVHQSD-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- KHUXNRRPPZOJPT-UHFFFAOYSA-N phenoxy radical Chemical class O=C1C=C[CH]C=C1 KHUXNRRPPZOJPT-UHFFFAOYSA-N 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
REFERIDA A UN COMPUESTO DERIVADO DE PIRAZOL DE FORMULA (I), DONDE RI ES UN HETEROCICLO, DONDE R1a ES ALQUILO C1-C7 OPCIONALMENTE SUSTITUIDO CON UNO O VARIOS ATOMOS DE HALOGENO, ALCOXI C1-C4, TRIFLUOROMETOXI, FENOXI, ENTRE OTROS, FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R1b ES ALQUILO C1-C7 OPCIONALMENTE SUSTITUIDO CON UNO O VARIOS ATOMOS DE HALOGENO, ALCOXI C1-C4, TRIFLUOROMETOXI, FENOXI, ENTRE OTROS; R2 ES ALQUILO C1-C5 O CIANO; R3 Y R4 SON FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, RADICAL TRIFLUOROMETILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-TER-BUTIL-5-[1-(2-CLOROFENIL)-5-(4-CLOROFENIL)-4-METIL-1H-PIRAZOL-3-IL]-1,3,4-OXADIAZOL, 2-[1-(2-CLOROFENIL)-5-(4-CLOROFENIL)-4-METIL-1H-PIRAZOL-3-IL]-5-ISOPROPIL-1,3,4-OXADIAZOL, 2-TER-BUTIL-5-[5-(4-CLOROFENIL)-1-(2,4-DICLOROFENIL)-4-METIL-1H-PIRAZOL-3-IL]-1,3,4-OXADIAZOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES CANABINOIDES CB1 Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS PSIQUIATRICOS COMO LA ANSIEDAD, DEPRESION, INSOMNIO, PSICOSIS, ESQUIZOFRENIA, ENTRE OTRAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0501860A FR2882365B1 (fr) | 2005-02-21 | 2005-02-21 | Derives de 2-(1,5-diphenyl-1h-pyrazol-3-yl)-1,3,4-oxadiazole leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20061038A1 true PE20061038A1 (es) | 2006-11-24 |
Family
ID=35079215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2006000202A PE20061038A1 (es) | 2005-02-21 | 2006-02-17 | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7632852B2 (es) |
| EP (1) | EP1853595A1 (es) |
| JP (1) | JP4812778B2 (es) |
| KR (1) | KR20070107053A (es) |
| CN (1) | CN101119990A (es) |
| AR (1) | AR055560A1 (es) |
| AU (1) | AU2006215443A1 (es) |
| BR (1) | BRPI0606845A2 (es) |
| CA (1) | CA2597359A1 (es) |
| DO (1) | DOP2006000045A (es) |
| EA (1) | EA200701779A1 (es) |
| FR (1) | FR2882365B1 (es) |
| GT (1) | GT200600082A (es) |
| IL (1) | IL185163A0 (es) |
| MA (1) | MA29261B1 (es) |
| MX (1) | MX2007009994A (es) |
| NO (1) | NO20074763L (es) |
| NZ (1) | NZ560790A (es) |
| PA (1) | PA8663901A1 (es) |
| PE (1) | PE20061038A1 (es) |
| SV (1) | SV2007002422A (es) |
| TW (1) | TW200640916A (es) |
| UY (1) | UY29388A1 (es) |
| WO (1) | WO2006087480A1 (es) |
| ZA (1) | ZA200706953B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
| CA2666193A1 (en) | 2006-08-08 | 2008-02-14 | Sanofi-Aventis | Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use |
| KR101100028B1 (ko) * | 2006-09-29 | 2011-12-29 | 주식회사 녹십자 | 칸나비노이드 ｃｂ1 수용체 길항제로서의 헤테로아릴-피라졸 유도체 |
| US7875647B2 (en) | 2006-09-29 | 2011-01-25 | Green Cross Corporation | Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists |
| US20080207704A1 (en) * | 2007-02-27 | 2008-08-28 | The Green Cross Corporation | Heteroaryl-imidazole derivatives as cannabinoid cb1 receptor antagonists |
| US7705024B2 (en) | 2007-04-12 | 2010-04-27 | National Health Research Institutes | Oxadiazole compounds |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2009078498A1 (en) * | 2007-12-17 | 2009-06-25 | Green Cross Corporation | Biarylpyrazole 4-carboxamides as cannabinoid cb1 receptor ligands |
| UY31968A (es) | 2008-07-09 | 2010-01-29 | Sanofi Aventis | Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos |
| WO2010035915A1 (en) * | 2008-09-25 | 2010-04-01 | Green Cross Corporation | Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683700B1 (de) | 2011-03-08 | 2015-02-18 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CN109651350B (zh) * | 2019-01-11 | 2022-05-24 | 贵州大学 | 一类杂环取代的1,3,4-噁(噻)二唑类化合物及其制备方法和用途 |
| CN109942567B (zh) * | 2019-04-30 | 2023-04-07 | 贵州大学 | 一种1,3,4-噁(噻)二唑基的咪唑类化合物及其制备方法和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09124571A (ja) * | 1995-11-01 | 1997-05-13 | Japan Tobacco Inc | アミド化合物及びその用途 |
| FR2758723B1 (fr) * | 1997-01-28 | 1999-04-23 | Sanofi Sa | Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments |
| US6825209B2 (en) * | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
| EP1556373A1 (en) * | 2002-10-18 | 2005-07-27 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
| CA2505945A1 (en) * | 2002-12-02 | 2004-06-17 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives useful as cox-i inhibitors |
| FR2856683A1 (fr) * | 2003-06-25 | 2004-12-31 | Sanofi Synthelabo | Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application en therapeutique |
-
2005
- 2005-02-21 FR FR0501860A patent/FR2882365B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-17 MX MX2007009994A patent/MX2007009994A/es not_active Application Discontinuation
- 2006-02-17 KR KR1020077019014A patent/KR20070107053A/ko not_active Withdrawn
- 2006-02-17 JP JP2007555667A patent/JP4812778B2/ja not_active Expired - Fee Related
- 2006-02-17 ZA ZA200706953A patent/ZA200706953B/xx unknown
- 2006-02-17 NZ NZ560790A patent/NZ560790A/en unknown
- 2006-02-17 EA EA200701779A patent/EA200701779A1/ru unknown
- 2006-02-17 EP EP06709338A patent/EP1853595A1/fr not_active Withdrawn
- 2006-02-17 CN CNA2006800049844A patent/CN101119990A/zh active Pending
- 2006-02-17 WO PCT/FR2006/000368 patent/WO2006087480A1/fr not_active Ceased
- 2006-02-17 BR BRPI0606845-6A patent/BRPI0606845A2/pt not_active IP Right Cessation
- 2006-02-17 AU AU2006215443A patent/AU2006215443A1/en not_active Abandoned
- 2006-02-17 PE PE2006000202A patent/PE20061038A1/es not_active Application Discontinuation
- 2006-02-17 CA CA002597359A patent/CA2597359A1/fr not_active Abandoned
- 2006-02-20 DO DO2006000045A patent/DOP2006000045A/es unknown
- 2006-02-20 GT GT200600082A patent/GT200600082A/es unknown
- 2006-02-20 TW TW095105632A patent/TW200640916A/zh unknown
- 2006-02-21 UY UY29388A patent/UY29388A1/es not_active Application Discontinuation
- 2006-02-21 SV SV2006002422A patent/SV2007002422A/es unknown
- 2006-02-21 AR ARP060100610A patent/AR055560A1/es unknown
- 2006-02-21 PA PA20068663901A patent/PA8663901A1/es unknown
-
2007
- 2007-08-08 US US11/835,670 patent/US7632852B2/en not_active Expired - Fee Related
- 2007-08-09 IL IL185163A patent/IL185163A0/en unknown
- 2007-08-23 MA MA30157A patent/MA29261B1/fr unknown
- 2007-09-18 NO NO20074763A patent/NO20074763L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| SV2007002422A (es) | 2007-01-17 |
| GT200600082A (es) | 2006-10-19 |
| KR20070107053A (ko) | 2007-11-06 |
| CA2597359A1 (fr) | 2006-08-24 |
| DOP2006000045A (es) | 2006-11-15 |
| ZA200706953B (en) | 2009-03-25 |
| UY29388A1 (es) | 2006-10-02 |
| CN101119990A (zh) | 2008-02-06 |
| AR055560A1 (es) | 2007-08-22 |
| NO20074763L (no) | 2007-11-16 |
| PA8663901A1 (es) | 2006-12-07 |
| US20080039510A1 (en) | 2008-02-14 |
| EP1853595A1 (fr) | 2007-11-14 |
| US7632852B2 (en) | 2009-12-15 |
| FR2882365A1 (fr) | 2006-08-25 |
| EA200701779A1 (ru) | 2008-02-28 |
| FR2882365B1 (fr) | 2007-09-07 |
| MX2007009994A (es) | 2007-10-10 |
| TW200640916A (en) | 2006-12-01 |
| WO2006087480A1 (fr) | 2006-08-24 |
| NZ560790A (en) | 2009-08-28 |
| MA29261B1 (fr) | 2008-02-01 |
| JP4812778B2 (ja) | 2011-11-09 |
| AU2006215443A1 (en) | 2006-08-24 |
| BRPI0606845A2 (pt) | 2009-07-21 |
| JP2008530188A (ja) | 2008-08-07 |
| IL185163A0 (en) | 2007-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
| PE20131377A1 (es) | Triazina-oxadiazoles | |
| PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
| PE20091339A1 (es) | Derivados de oxadiazol con actividad sobre receptores s1p1 | |
| PE20142099A1 (es) | Derivados de sulfonamida | |
| PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| PE20080895A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| PE20090592A1 (es) | Nuevos derivados de piperazina-amida | |
| PE20081229A1 (es) | Antagonistas de receptor de orexina de diazepam sustituido | |
| PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
| PE20091925A1 (es) | Derivados de indazol sustituidos con fenilo o benzodioxinilo | |
| AR044163A1 (es) | Derivados de pirazol sustituidos, composiciones farmaceuticas que los contienen y compuestos relacionados como antagonistas del receptor de bradiquinina b1 | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
| AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
| PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| PE20120101A1 (es) | Pirazoles fungicidas | |
| PE20060306A1 (es) | Compuestos de heteroaril-amida sustituida | |
| PE20091026A1 (es) | Piperidinas heteroaril-sustituidas | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| PE20081851A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR079550A1 (es) | Derivados de pirazol | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| AR062679A1 (es) | Derivados de eter diarilico y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |